Top-News
Pharmazeutika Japan

Astellas Pharma News

Aktie
WKN:  856273 ISIN:  JP3942400007 US-Symbol:  ALPMF
9,296 €
+0,05 €
+0,54%
07.05.24 08:09:10
Handeln Depot/Watchlist
Aktienanzahl *
1,82 Mrd.
Marktkapitalisierung *
17,28 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nikkei 225
IR-Website
zur Website
*Stand: 15.01.2024

Astellas Pharma News

02.05.23 - Der Aktionär
Übernahme‑Kracher: Astellas Pharma schlägt zu
10.06.22 - DGAP
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Research Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis 10-Jun-2022 / 01:00 GMT/BST
02.06.21 - Börse Online
Morphosys schluckt US-Krebsspezialisten - Aktie bricht ein
Das Biotechunternehmen Morphosys greift für bis zu 1,7 Milliarden Dollar nach dem US-​Krebsspezialisten Constellation Pharmaceuticals. Morphosys bietet 34 Dollar je ...
13.08.19 - DGAP
Ludwig Beck am Rathauseck-Textilhaus Feldmeier AG: Veränderungen im Vorstand der LUDWIG BECK AG
DGAP-News: Ludwig Beck am Rathauseck-​Textilhaus Feldmeier AG / Schlagwort(e): Personalie/Personalie Ludwig Beck am Rathauseck-​Textilhaus Feldmeier AG: Veränderungen ...
15.09.17 - Handelsblatt
Anleger unbeeindruckt von Nordkoreas Raketentest
Nordkorea hat erneut einen Raketentest vollzogen, das Geschoss soll sogar über Japan hinweggeflogen sein. Die Investoren an den asiatischen Märkten lässt das aber kalt. Im ...
18.05.17 - ARIVA.DE Redaktion
Die Aktie von Astellas Pharma läuft schlechter: Große Kurs­verluste!
Keinen Grund zur Freude haben Anleger, die in die Astellas Pharma-​Aktie investiert haben: Der Kurs der Aktie sackt kräftig ab.
17.05.17 - ARIVA.DE Redaktion
Astellas Pharma-Aktie leicht im Plus
Im Wertpapierhandel notiert der Anteilsschein von Astellas Pharma aktuell etwas fester. Der jüngste Kurs betrug 11,71 Euro.
23.04.17 - PR Newswire
Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing Recurrence
Use of Extended-​Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) ...
20.04.17 - PR Newswire
New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Additional 10,670 Bed Days a Year
New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Additional 10,670 Bed Days a Year PR Newswire
12.12.16 - PR Newswire
Astellas Announces Transfer of Qutenza™ to Grünenthal
Astellas Announces Transfer of Qutenza™ to Grünenthal PR Newswire
28.10.16 - PR Newswire
Astellas to Acquire Ganymed Pharmaceuticals
Astellas to Acquire Ganymed Pharmaceuticals PR Newswire
14.10.16 - PR Newswire
World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
World Anti-​Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports PR Newswire
14.10.16 - PR Newswire
World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
World Anti-​Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports PR Newswire
11.04.16 - PR Newswire
International Consensus Report Highlights Need for Improved Management of Clostridium difficile Infection (CDI) in Inflammatory Bowel Disease (IBD) Patients
International Consensus Report Highlights Need for Improved Management of Clostridium difficile Infection (CDI) in Inflammatory Bowel Disease (IBD) Patients PR Newswire
04.03.16 - PR Newswire
Astellas Pharma Europe Ltd. Announces New President of EMEA Operations
Astellas Pharma Europe Ltd. Announces New President of EMEA Operations PR Newswire
04.03.16 - ots
Astellas Pharma Europe Ltd. Announces New President of EMEA ...
Astellas Pharma Europe Ltd. Announces New President of EMEA Operations Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma ...
02.12.15 - ots
Biovista Inc. gibt Zusammenarbeit mit Astellas Pharma zwecks ...
Biovista Inc. gibt Zusammenarbeit mit Astellas Pharma zwecks Umpositionierung von Arzneimitteln bekannt Charlottesville, Virginia (ots/PRNewswire) - Biovista gab heute den ...
10.11.15 - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Astella
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale ...
18.09.15 - PR Newswire
Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP)
Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP) PR Newswire
16.09.15 - PR Newswire
Astellas Pharma EMEA beruft Eugene Van Rensburg zum Chief Financial Officer
Astellas Pharma EMEA beruft Eugene Van Rensburg zum Chief Financial Officer PR Newswire

Newssuche

Videos

07.05.24 +43,15%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »